This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): IMMU-100, CEA-cide
Description: 131I-labetuzumab is a radioactive monoclonal antibody that targets carcinoembryonic antigen (CEA), a protein found in many types of visceral cells and in the developing fetus. Its clinical utility to date has been as a “tumor marker,” a protein whose measurements can be followed in order to monitor disease course. Elevated CEA levels are most often associated with cancers of the colon and rectum.
Additional information available to subscribers only: